2. Search Result
Search Result
Results for "

Palbociclib

" in MedChemExpress (MCE) Product Catalog:

19

Inhibitors & Agonists

5

Isotope-Labeled Compounds

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-50767
    Palbociclib
    Maximum Cited Publications
    134 Publications Verification

    PD 0332991

    		 CDK Cancer
    Palbociclib (PD 0332991) is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .
    <em>Palbociclib</em>
  • HY-50767C
    Palbociclib hydrochloride
    115+ Cited Publications

    PD-0332991 hydrochloride

    		 CDK Cancer
    Palbociclib (PD 0332991) hydrochloride is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib hydrochloride has potent anti-proliferative activity and induces cell cycle arrest in cancer cells. Palbociclib hydrochloride can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .
    <em>Palbociclib</em> hydrochloride
  • HY-50767S
    Palbociclib-d8

    PD 0332991-d8

    		 CDK Cancer
    Palbociclib-d8 is a deuterium labeled Palbociclib. Palbociclib is a selective and orally active CDK4 and CDK6 inhibitor with IC50s of 11 and 16 nM, respectively. Palbociclib has the potential for ER-positive and HER2-negative breast cancer research[1].
    <em>Palbociclib</em>-d8
  • HY-50767S1
    Palbociclib-d4 hydrochloride

    PD 0332991-d4 hydrochloride

    		 Isotope-Labeled Compounds CDK Cancer
    Palbociclib-d4 (hydrochloride) is the deuterium labeled Palbociclib hydrochloride. Palbociclib (PD 0332991) is a selective CDK4 and CDK6 inhibitor with IC50s of 11 and 16 nM, respectively. Palbociclib has the potential for ER-positive and HER2-negative breast cancer research[1].
    <em>Palbociclib</em>-d4 hydrochloride
  • HY-50767B
    Palbociclib dihydrochloride

    PD-0332991 dihydrochloride

    		 CDK Cancer
    Palbociclib (PD 0332991) dihydrochloride is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib dihydrochloride has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .
    <em>Palbociclib</em> dihydrochloride
  • HY-50767D
    Palbociclib orotate

    PD 0332991 orotate

    		 CDK Cancer
    Palbociclib (PD 0332991) orotate is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib orotate has potent anti-proliferative activity and induces cell cycle arrest in cancer cells. Palbociclib orotate can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .
    <em>Palbociclib</em> orotate
  • HY-50767A
    Palbociclib monohydrochloride
    Maximum Cited Publications
    134 Publications Verification

    PD 0332991 monohydrochloride

    		 CDK Cancer
    Palbociclib (PD 0332991) monohydrochloride is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib monohydrochloride has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .
    <em>Palbociclib</em> monohydrochloride
  • HY-A0065
    Palbociclib isethionate
    Maximum Cited Publications
    134 Publications Verification

    PD 0332991 isethionate

    		 CDK Cancer
    Palbociclib (PD 0332991) isethionate is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib isethionate has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .
    <em>Palbociclib</em> isethionate
  • HY-130296
    Palbociclib-propargyl

    PROTAC CDK6 ligand 1

    		 Ligands for Target Protein for PROTAC Cancer
    Palbociclib-propargyl is a ligand for target protein CDK6 for PROTAC, and binds to CRBN ligand via a PEG linker to make a PROTAC CP-10. CP-10 shows a DC50 of 2.1 nM for CDK6 . Palbociclib-propargyl is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    <em>Palbociclib</em>-propargyl
  • HY-131466
    N-Methyl Palbociclib

    		Drug Metabolite Others
    N-Methyl Palbociclib is an impurity of Palbociclib (HY-50767). Palbociclib (PD 0332991) is an orally active selective CDK4 and CDK6 inhibitor.
    N-Methyl <em>Palbociclib</em>
  • HY-151454S
    N-Formyl palbociclib-d8

    		Isotope-Labeled Compounds Others
    N-Formyl palbociclib-d8 is the deuterium-labeled N-Formyl palbociclib.
    N-Formyl <em>palbociclib</em>-d8
  • HY-136250
    BSJ-03-204

    		PROTACs CDK Cancer
    BSJ-03-204 is a PROTAC connected by ligands for Cereblon and CDK. BSJ-03-204 is a potent and selective Palbociclib-based CDK4/6 dual degrader (PROTAC), with IC50s of 26.9 nM and 10.4 nM for CDK4/D1 and CDK6/D1, respectively. BSJ-03-204 does not induce IKZF1/3 degradation and has anti-cancer activity .
    BSJ-03-204
  • HY-136250A
    BSJ-03-204 triTFA

    		PROTACs CDK Cancer
    BSJ-03-204 triTFA is a PROTAC connected by ligands for Cereblon and CDK. BSJ-03-204 triTFA is a potent and selective Palbociclib-based CDK4/6 dual degrader (PROTAC), with IC50s of 26.9 nM and 10.4 nM for CDK4/D1 and CDK6/D1, respectively. BSJ-03-204 triTFA does not induce IKZF1/3 degradation and has anti-cancer activity .
    BSJ-03-204 triTFA
  • HY-158106
    AZD8421

    		CDK Cancer
    AZD8421 is a selective CDK2 inhibitor (IC50: 9 nM) with selectivity for CDK1, CDK4 and CDK6. AZD8421 inhibits cancer cell proliferation by inhibiting pRB phosphorylation, inducing cell cycle arrest and senescence. AZD8421 demonstrated promising single efficacy and synergy with CDK4/6 inhibitors such as Palbociclib (HY-50767) in in vivo breast and ovarian models. AZD8421 also has potent single-agent inhibitory activity against drug-resistant breast cancer cells.
    AZD8421
  • HY-A0064
    Verapamil hydrochloride
    40+ Cited Publications

    (±)-Verapamil hydrochloride; CP-16533-1 hydrochloride

    		 Calcium Channel P-glycoprotein Cytochrome P450 Cardiovascular Disease
    Verapamil hydrochloride ((±)-Verapamil hydrochloride) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil hydrochloride also inhibits CYP3A4. Verapamil hydrochloride has the potential for high blood pressure, heart arrhythmias and angina research .
    Verapamil hydrochloride
  • HY-14275
    Verapamil
    40+ Cited Publications

    (±)-Verapamil; CP-16533-1

    		 Calcium Channel P-glycoprotein Cytochrome P450 Metabolic Disease Cancer
    Verapamil ((±)-Verapamil) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil also inhibits CYP3A4. Verapamil has the potential for high blood pressure, heart arrhythmias and angina research .
    Verapamil
  • HY-A0064S1
    Verapamil-d6 hydrochloride

    (±)-Verapamil-d6 hydrochloride; CP-16533-1-d6 hydrochloride

    		 Isotope-Labeled Compounds Cardiovascular Disease
    Verapamil-d6 (CP-16533-1-d6) hydrochloride is the deuterium labled Verapamil (hydrochloride) (HY-A0064). Verapamil hydrochloride ((±)-Verapamil hydrochloride) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil hydrochloride also inhibits CYP3A4. Verapamil hydrochloride has the potential for high blood pressure, heart arrhythmias and angina research .
    Verapamil-d6 hydrochloride
  • HY-136589
    Verapamil EP Impurity C hydrochloride

    NSC-609249 hydrochloride

    		 Calcium Channel P-glycoprotein Cytochrome P450 Metabolic Disease
    NSC-609249 hydrochloride is an impurity of Verapamil (HY-14275). Verapamil is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor .
    Verapamil EP Impurity C hydrochloride
  • HY-14275S1
    Verapamil-d7

    (±)-Verapamil-d7; CP-16533-1-d7

    		 Isotope-Labeled Compounds Calcium Channel P-glycoprotein Cytochrome P450 Metabolic Disease Cancer
    Verapamil-d7 is the deuterium labeled Verapamil (HY-14275). Verapamil ((±)-Verapamil) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil also inhibits CYP3A4. Verapamil has the potential for high blood pressure, heart arrhythmias and angina research .
    Verapamil-d7

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: